Real-world data on the PI3Kd inhibitor idelalisib in relapsed/refractory CLL patients treated in Sweden

导出原文传递

翻译打印收藏纠错

作者： Mattsson, Agnes ^[1] ; Sylvan, Sandra ^[2] ; Mulder, Tom ^[3] ; Axelsson, Per ^[4] ; Ellin, Fredrik ^[5] ; Lewerin, Catharina ^[6] ; Uggla, Bertil ^[7] ; Osterborg, Anders ^[8] ; Hansson, Lotta

作者单位： Soder Sjukhuset, Dept Internal Med, Stockholm, Sweden ^[1] Sahlgrens Univ Hosp, Sect Hematol & Coagulat, Gothenburg, Sweden ^[2] Karolinska Univ Hosp, Dept Hematol, Solna, Sweden ^[3] Univ Hosp Orebro, Dept Med, Orebro, Sweden ^[4] Karolinska Univ Hosp Solna, Dept Hematol, Solna, Sweden ^[5] Kalmar Cty Hosp, Dept Med, Kalmar, Sweden ^[6] Helsingborgs Hosp, Dept Hematol, Helsingborg, Sweden ^[7] Karolinska Inst, Stockholm, Sweden ^[8]

发布时间 2020-10-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Leukemia and lymphoma

2020年61卷S1期

66-67页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Real-world data on the PI3Kd inhibitor idelalisib in relapsed/refractory CLL patients treated in Sweden

Leukemia and lymphoma

相似文献

Leukemia and lymphoma

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Real-world data on the PI3Kd inhibitor idelalisib in relapsed/refractory CLL patients treated in Sweden

Leukemia and lymphoma

相似文献

Leukemia and lymphoma

相关期刊

检索历史清除